Norgestimate/Ethinyl Estradiol Oral Tablets
Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/de84f0ffa0574dd6a022fb7dbd91d110/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE is modifying contract SPE2D220D0090 to correct an administrative error for the procurement of Norgestimate/Ethinyl Estradiol Oral Tablets. Norgestimate/Ethinyl Estradiol Oral Tablets are typically used for contraception and hormone replacement therapy.

    Point(s) of Contact
    Denise Taubman
    (215) 737-6877
    denise.taubman@dla.mil
    Files
    Title
    Posted
    SPE2D220D0090P0001.pdf
    Lifecycle
    Title
    Type
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Currently viewing
    Special Notice
    Similar Opportunities
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking Norgestimate/Ethinyl Estradiol Oral Tablets. These tablets are typically used for oral contraception.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a presolicitation for a national requirements contract for Norgestimate/Ethinyl Estradiol Tablets. The procurement will include various formulations of these oral tablets, specifically Norgestimate Ethinyl Estradiol Triphasic Low Dose Oral Tablets and Ethinyl Estradiol/Norgestimate tablets, packaged in 3x28 count packs. This contract is crucial for establishing a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable provision of these essential pharmaceuticals. Interested parties should prepare for the solicitation, projected for November 2024, and may contact Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for further inquiries.
    ESTRADIOL TABLETS
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is seeking ESTRADIOL TABLETS. ESTRADIOL TABLETS are typically used for hormone replacement therapy and the treatment of menopause symptoms.
    6505--Norethindrone 5mg Tablet (VA-25-00005551)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for the supply of Norethindrone Acetate Tablets under Request for Proposal (RFP) 36E79724R0027. The procurement aims to establish contracts for the pharmaceutical product, with specific requirements regarding pricing for a base year and four option years, compliance with packaging standards, and adherence to the Drug Supply Chain Security Act (DSCSA) regulations. This medication is essential for various health treatments within the VA system, ensuring that veterans receive necessary pharmaceutical care. Interested contractors must submit their proposals by November 15, 2024, at 2:30 PM Central Standard Time, to the designated email addresses provided in the solicitation documents. For further inquiries, potential bidders can contact Contracting Officer Adrienne A Albachiara at Adrienne.Albachiara@va.gov.
    Estradiol Patches
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking Estradiol Patches. Estradiol Patches are typically used for hormone replacement therapy in women to alleviate symptoms of menopause such as hot flashes, vaginal dryness, and mood swings. The place of performance for this procurement is DLA Troop Support, 700 Robbins Avenue, Philadelphia, PA 19111, USA. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 215-737-4778.
    Dextroamphetamine/Amphetamine National Contract
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is a procurement notice from the DEFENSE LOGISTICS AGENCY, specifically the DLA TROOP SUPPORT office. This notice falls under the category of MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES with a PSC code of 6515. The primary contact for this contract is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 215-737-8677. The notice describes an amendment, P00006, which incorporates additional clauses to the existing contract.
    Metformin HCL ER
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Metformin HCL ER. Metformin HCL ER is a drug used to treat type 2 diabetes. This procurement is being conducted by DLA TROOP SUPPORT. For more information, contact Christopher Newman at christopher.newman@dla.mil or 2157372905.
    Finasteride Tablets
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Finasteride Tablets. Finasteride Tablets are typically used for the treatment of male pattern hair loss and benign prostatic hyperplasia. This procurement is for the incorporation of new clauses into an existing contract.
    Lamotrigine
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Lamotrigine ER Tablets, specifically in dosages of 25MG, 50MG, 100MG, 200MG, 250MG, and 300MG, packaged in 30 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health service customers, including the Bureau of Prisons and the Department of Veterans Affairs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should prepare for the solicitation, projected for November 2024, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or by phone at 215-737-4955.
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.